FSCO · Form 8-K · FS Credit Opportunities Corp.

⌘K

Filings	Filing Date	Form Type	Company	Description	AI	Link

FSCO · Form 8-K · FS Credit Opportunities Corp. | Signal8

Insider transactionsFund filings

Sort

Filings				Description
DFDVDeFi Development Corp. Nov 9, 2026 · 8:15 AM ET 8-K 8.01Other events9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:15 AM ET	8-K	DFDV DeFi Development Corp.	8.01Other events9.01ExhibitsExhibits:EX-99.1
MTEKMaris Tech Ltd. Nov 9, 2026 · 8:15 AM ET 6-K6-K Exhibits:EX-99.1	Nov 9, 20268:15 AM ET	6-K	MTEK Maris Tech Ltd.	Exhibits:EX-99.1 6-K
HRTXHERON THERAPEUTICS, INC. /DE/ Nov 9, 2026 · 8:15 AM ET 8-K Heron Therapeutics announced Q3 2026 net revenue of $35.3 million, down 7.8% year over yea… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:15 AM ET	8-K	HRTX HERON THERAPEUTICS, INC. /DE/	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Heron Therapeutics announced Q3 2026 net revenue of $35.3 million, down 7.8% year over year, with a net loss of $5.0 million and $23.4 million in cash at quarter end. The Acute Ca…
CNCKCoincheck Group N.V. Nov 9, 2026 · 8:14 AM ET 6-K Coincheck Group N.V. (NASDAQ: CNCK) reported fiscal Q2 2027 results showing total revenue… Exhibits:EX-99	Nov 9, 20268:14 AM ET	6-K	CNCK Coincheck Group N.V.	Exhibits:EX-99 Coincheck Group N.V. (NASDAQ: CNCK) reported fiscal Q2 2027 results showing total revenue fell 43% YoY to ¥75.5 billion ($480 million), driven by a 56% drop in Marketplace Trading…
KRFGKing Resources Global, Inc. Nov 9, 2026 · 8:12 AM ET 8-K King Resources Global's subsidiary Heavenly Grace Limited signed three purchase agreements… 1.01Material agreement9.01ExhibitsExhibits:EX-10.1EX-10.2+1	Nov 9, 20268:12 AM ET	8-K	KRFG King Resources Global, Inc.	1.01Material agreement9.01ExhibitsExhibits:EX-10.1EX-10.2+1 King Resources Global's subsidiary Heavenly Grace Limited signed three purchase agreements on November 5, 2026 with Hong Kong's Grand View Assets Management Limited to buy 19 colle…
MREOMereo BioPharma Group plc Nov 9, 2026 · 8:10 AM ET 8-K Mereo BioPharma reported Q3 2026 results with a net loss of $5.9 million, improved from $7… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:10 AM ET	8-K	MREO Mereo BioPharma Group plc	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Mereo BioPharma reported Q3 2026 results with a net loss of $5.9 million, improved from $7.0 million a year earlier, as R&D spending was cut to $2.1 million from $4.3 million and G…
NVONOVO NORDISK A S Nov 9, 2026 · 8:09 AM ET 6-K Novo Nordisk filed a 6-K updating the market on its ongoing share repurchase programme, re…	Nov 9, 20268:09 AM ET	6-K	NVO NOVO NORDISK A S	Novo Nordisk filed a 6-K updating the market on its ongoing share repurchase programme, reporting daily buyback transactions from 3 to 6 November 2026 under the DKK 15 billion prog…
Trinseo PLC Nov 9, 2026 · 8:09 AM ET 8-K Trinseo reported Q3 2026 net sales of $779 million (up 5% YoY) and a net loss of $49 milli… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20268:09 AM ET	8-K	Trinseo PLC	2.02Results of operations9.01ExhibitsExhibits:EX-99.1EX-99.2 Trinseo reported Q3 2026 net sales of $779 million (up 5% YoY) and a net loss of $49 million, a $61 million improvement versus the prior year, with Adjusted EBITDA of $51 million u…
OPALOPAL Fuels Inc. Nov 9, 2026 · 8:07 AM ET 8-K OPAL Fuels reported Q3 2026 Adjusted EBITDA of $26.7 million, up 32% year-over-year and in… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:07 AM ET	8-K	OPAL OPAL Fuels Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 OPAL Fuels reported Q3 2026 Adjusted EBITDA of $26.7 million, up 32% year-over-year and in line with expectations, driven by RNG production growth, Fuel Station Services, 45Z contr…
QTRXQuanterix Corp Nov 9, 2026 · 8:07 AM ET 8-K Quanterix reported Q3 2026 revenue of $35.0 million, up 6.3% sequentially and ahead of exp… 2.02Results of operations7.01Reg FD9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20268:07 AM ET	8-K	QTRX Quanterix Corp	2.02Results of operations7.01Reg FD9.01ExhibitsExhibits:EX-99.1EX-99.2 Quanterix reported Q3 2026 revenue of $35.0 million, up 6.3% sequentially and ahead of expectations, though still down 13% year-over-year amid continued market softness. The compa…
UNITUniti Group Inc. Nov 9, 2026 · 8:07 AM ET 8-K Uniti Group reported Q3 2026 revenue of $848.1 million, up from $722.6 million a year ago,… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:07 AM ET	8-K	UNIT Uniti Group Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Uniti Group reported Q3 2026 revenue of $848.1 million, up from $722.6 million a year ago, alongside a net loss of $244.5 million and Adjusted EBITDA of $289.3 million. The company…
ADCTADC Therapeutics SA Nov 9, 2026 · 8:06 AM ET 8-K ADC Therapeutics reported Q3 2026 net product revenue of $21.0 million, up 33% from $15.8… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:06 AM ET	8-K	ADCT ADC Therapeutics SA	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 ADC Therapeutics reported Q3 2026 net product revenue of $21.0 million, up 33% from $15.8 million a year ago, driven by volume growth for ZYNLONTA. Net loss narrowed to $25.3 milli…
LKQLKQ CORP Nov 9, 2026 · 8:05 AM ET 8-K LKQ Corporation announced that Salvatore A. Abbate will assume the role of President and C… 5.02Officer/director change9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:05 AM ET	8-K	LKQ LKQ CORP	5.02Officer/director change9.01ExhibitsExhibits:EX-99.1 LKQ Corporation announced that Salvatore A. Abbate will assume the role of President and CEO and join the Board effective November 9, 2026, accelerating his start from the previous…
JSPRJasper Therapeutics, Inc. Nov 9, 2026 · 8:05 AM ET 8-KJasper Therapeutics announced the results of its offer to purchase outstanding warrants fr… 8.01Other events9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:05 AM ET	8-K	JSPR Jasper Therapeutics, Inc.	8.01Other events9.01ExhibitsExhibits:EX-99.1 Jasper Therapeutics announced the results of its offer to purchase outstanding warrants from its September 18, 2025 public offering, which expired November 7, 2026. A total of 8,51…
SPRBSPRUCE BIOSCIENCES, INC. Nov 9, 2026 · 8:05 AM ET 8-K Spruce Biosciences reported a Q3 2026 net loss of $24.0 million ($8.51 per share), roughly… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:05 AM ET	8-K	SPRB SPRUCE BIOSCIENCES, INC.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Spruce Biosciences reported a Q3 2026 net loss of $24.0 million ($8.51 per share), roughly triple the $8.2 million loss a year earlier, driven by R&D spending that jumped to $18.1…
INMInMed Pharmaceuticals Inc. Nov 9, 2026 · 8:04 AM ET 8-KInMed Pharmaceuticals has completed its previously disclosed merger with Mentari Therapeut… 7.01Reg FD9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:04 AM ET	8-K	INM InMed Pharmaceuticals Inc.	7.01Reg FD9.01ExhibitsExhibits:EX-99.1 InMed Pharmaceuticals has completed its previously disclosed merger with Mentari Therapeutics. The combined company, named Mentari Therapeutics, Inc., begins trading on Nasdaq unde…
WHWKWhitehawk Therapeutics, Inc. Nov 9, 2026 · 8:04 AM ET 8-K Whitehawk Therapeutics reported Q3 2026 results with a net loss of $21.2 million versus $1… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:04 AM ET	8-K	WHWK Whitehawk Therapeutics, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Whitehawk Therapeutics reported Q3 2026 results with a net loss of $21.2 million versus $17.7 million a year ago, and R&D expense rising to $18.1 million from $14.3 million as its…
EVLVEvolv Technologies Holdings, Inc. Nov 9, 2026 · 8:03 AM ET 8-K Evolv Technologies (NASDAQ: EVLV) appointed Jason Blessing, 55, to its Board of Directors… 5.02Officer/director change7.01Reg FD9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:03 AM ET	8-K	EVLV Evolv Technologies Holdings, Inc.	5.02Officer/director change7.01Reg FD9.01ExhibitsExhibits:EX-99.1 Evolv Technologies (NASDAQ: EVLV) appointed Jason Blessing, 55, to its Board of Directors effective November 6, 2026, as an independent Class III director serving until the 2027 an…
DCTHDELCATH SYSTEMS, INC. Nov 9, 2026 · 8:02 AM ET 8-K Delcath Systems reported Q3 2026 revenue of $35.1 million, up 71% from $20.6 million in th… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:02 AM ET	8-K	DCTH DELCATH SYSTEMS, INC.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Delcath Systems reported Q3 2026 revenue of $35.1 million, up 71% from $20.6 million in the prior-year quarter, driven by $32.7 million in HEPZATO KIT sales in the U.S. and $2.4 mi…
RBARB GLOBAL INC. Nov 9, 2026 · 8:02 AM ET 8-K RB Global reported strong Q3 2026 results, with revenue up 17% year over year to $1.3 bill… 2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1	Nov 9, 20268:02 AM ET	8-K	RBA RB GLOBAL INC.	2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1 RB Global reported strong Q3 2026 results, with revenue up 17% year over year to $1.3 billion and gross transaction value up 20% to $4.7 billion. GAAP diluted EPS jumped 63% to $0.…

Searching Signal8’s SEC filing archive — filings from Oct 2021 onward.

1-20 of 10,000+ filings